Comprehensive Insight Generation for Product Development

Target RWE generates complete, longitudinal datasets with the power of advanced analytics and vigorous causal inference methodologies to uncover deep insights on unmet needs, disease progression, and the efficacy and safety of new treatments in the real world.

Schedule a Meeting

A Partner for Your Clinical Programs

With strong expertise in liver disease, gastroenterology, and dermatology, Target RWE’s multi-stakeholder model allows you to develop robust disease protocols to inform study objectives and endpoints. Our registries contain all relevant disease state variables, which when combined with our digital collection of patient and clinician reported outcomes and biosamples provide a framework for decisions on study entry criteria and site selection – reducing unnecessary procedures and costly protocol amendments.

Healthcare Research & Development Abstract Stock Photo

Demonstrate Valuable Insights with
Real-World Evidence

Target RWE’s cross-sectional and longitudinally complete registries encompass diverse patient populations beyond those traditionally captured in Phase 2 and 3 trials, generating more meaningful evidence on product effectiveness and safety in the real world. We provide insights on natural history of disease, treatment patterns, disease progression and other clinical questions. Execute your publication strategy with confidence and speed by joining our unique collaborative academic model, which taps not just into our patient registries but our network of leading clinical investigators.

Phases of Drug Development Stock Photo

Comprehensive Treatment Comparisons for Informed Decision Making

Leverage our proven advanced analytics and diverse real-world data to evaluate comparative effectiveness, safety, and cost-effectiveness of new therapies. Target RWE’s patient-centered analyses utilize patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) measures to inform disease burden, empowering you with the insights necessary to improve healthcare utilization.

HEOR Abstract Visual Stock

Real-World Data for Regulatory Compliance & Safety

Target RWE’s fit-for-purpose longitudinal registries, ability to incorporate clinician-reported outcomes, and validated analytics software provide comprehensive solutions to meet FDA and pharmacovigilance risk assessment committee requests for new drug applications. Our research collaboration agreement with the FDA, combined with proven experience in meeting post marketing commitments and managing adjudication committees, enable us to be your trusted partner for regulatory decision-making.

Regulatory and Pharmacovigilance Stock

Patient Insights for Strategic Product Positioning

Target RWE's detailed patient journeys identify meaningful data points in disease that can inform your product positioning and marketing plan. Our large datasets, combined with novel analytical and causal inference methodology identify patient phenotypes with high unmet need, predict disease progression, and support identification of patients who will benefit most from your new therapy.

 

Commercial Analytics Stock

Fit-for-Purpose Registries for Advanced Research

Target RWE collaborates with a renowned network of clinical investigators to enroll large patient cohorts, capturing up to 5 years of retrospective and 15 years of prospective follow-up – creating some of the largest and most comprehensive real-world patient registries in the U.S.

280+
Academic & Community Sites
6+
Therapeutic Areas
25+
Disease Indications
10,000+
Patients with Biosamples
400,000+
Liver Disease Patients
200+
Publications

New Publications

title

Pharmacoepidemiology

ISPE 2024- Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study

title

Epidemiology

Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study

title

Nonalcoholic Steatohepatitis (NASH)

EASL 2024- Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH

title

Nonalcoholic Steatohepatitis (NASH)

EASL 2024- A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

title

Gastroenterology

Time to Diagnosis Among Patients with Eosinophilic Esophagitis in the United States

title

Gastroenterology

Factors Predicting Loss of Remission in Crohn’s Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD

In the News

Oct 09 2024

Advancing RWE: Target RWE's Staging and Clean Room Committee Approaches Set New Benchmark

Aug 27 2024

ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour

Aug 21 2024

Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement Platform

Aug 21 2024

Sequential Nested Trial Emulation Presented by Real-World Evidence Leader Target RWE at ISPE 2024

Contact

Have a Question or Want to Learn More?

Fill in your contact information & a member from our team will be in contact.

By Submitting this form, you consent to your information used by Target RWE for the purpose of contacting you to better understand your potential interest in Target RWE and/or its services. For more information, see our privacy policy.